UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

Blood, 2004-11, Vol.104 (10), p.3064-3071

2004

Link zum Volltext

Verfügbarkeit prüfen

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

British journal of haematology, 2008-10, Vol.143 (2), p.191-200

2008

Link zum Volltext

Verfügbarkeit prüfen

Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e15787-e15787

2017

Link zum Volltext

Verfügbarkeit prüfen

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

Leukemia & lymphoma, 2009-01, Vol.50 (5), p.716-722

2009

Link zum Volltext

Verfügbarkeit prüfen

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

Journal of cancer research and clinical oncology, 2013-03, Vol.139 (3), p.499-508

2013

Link zum Volltext

Verfügbarkeit prüfen

A new concept for the differential diagnosis and therapy of anaemia in cancer patients

Supportive care in cancer, 2011-02, Vol.19 (2), p.261-269

2011

Link zum Volltext

Verfügbarkeit prüfen

Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.4009-4009

2013

Link zum Volltext

Verfügbarkeit prüfen

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients

British journal of haematology, 2008-06, Vol.141 (5), p.631-640

2008

Link zum Volltext

Verfügbarkeit prüfen

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Blood, 2012-11, Vol.120 (21), p.1855-1855

2012

Link zum Volltext

Verfügbarkeit prüfen

Bacillary angiomatosis

Journal der Deutschen Dermatologischen Gesellschaft, 2009-09, Vol.7 (9), p.767-769

2009

Link zum Volltext

Verfügbarkeit prüfen

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

Blood, 2008-11, Vol.112 (11), p.4578-4578

2008

Link zum Volltext

Verfügbarkeit prüfen

Bazilläre Angiomatose

Journal der Deutschen Dermatologischen Gesellschaft, 2009-09, Vol.7 (9), p.767-769

2009

Link zum Volltext

Verfügbarkeit prüfen

Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma

Blood, 2007-11, Vol.110 (11), p.2723-2723

2007

Link zum Volltext

Verfügbarkeit prüfen

Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study

Blood, 2007-11, Vol.110 (11), p.4474-4474

2007

Link zum Volltext

Verfügbarkeit prüfen

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma

Blood, 2006-11, Vol.108 (11), p.2449-2449

2006

Link zum Volltext

Verfügbarkeit prüfen

Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Conventional Chemotherapy: Final Results of a Phase I Study

Blood, 2005-11, Vol.106 (11), p.5154-5154

2005

Link zum Volltext

Verfügbarkeit prüfen

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL)

Blood, 2004-11, Vol.104 (11), p.584-584

2004

Link zum Volltext

Verfügbarkeit prüfen

Bacillary angiomatosis

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009, Vol.7 (9), p.767-769

2009

Link zum Volltext

Verfügbarkeit prüfen

Bazilläre Angiomatose

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 2009, Vol.7 (9), p.767-769

2009

Link zum Volltext

Verfügbarkeit prüfen

BODY MOVEMENT IN RELATION TO TYPE OF INFORMATION (PERSON- AND NONPERSON-ORIENTED) AND COGNITIVE STYLE (FIELD DEPENDENCE)

Human communication research, 1977-10, Vol.4 (1), p.19

1977

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(35)
Mit Volltextzugriff
(32)

Publikationsform

Sprache

Englisch
(39)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Humans
(17)
Male
(15)
Life Sciences & Biomedicine
(14)
Science & Technology
(14)
Female
(11)
Adult
(9)
Middle Aged
(9)
Aged
(8)
Biological And Medical Sciences
(8)
Medical Sciences
(8)
Hematologic And Hematopoietic Diseases
(6)
Hematology
(6)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(6)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(5)
Field Dependence-Independence
(5)
Oncology
(4)
Psychology
(4)
Social Sciences
(4)
Adolescent
(3)
Aged, 80 And Over
(3)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Rituximab Added to First-Line Mitoxantrone, Chlorambucil, and Prednisolone Chemotherapy Followed by Interferon Maintenance Prolongs Survival in Patients With Advanced Follicular Lymphoma: An East German Study Group Hematology and Oncology Study

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

Modified IPCW model: A method for adjusting for bias in the estimation of overall survival due to the use of second and third line therapies in locally advanced or metastatic pancreatic cancer patients

A novel regimen combining high dose cytarabine and bortezomib has activity in multiply relapsed and refractory mantle cell lymphoma - long-term results of a multicenter observation study

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

A new concept for the differential diagnosis and therapy of anaemia in cancer patients

Phase II, randomized, double-blind placebo-controlled trial of nimotuzumab plus gemcitabine compared with gemcitabine alone in patients (pts) with advanced pancreatic cancer (PC)

Rapid and sustained clearance of circulating lymphoma cells after chemotherapy plus rituximab: clinical significance of quantitative t(14;18) PCR monitoring in advanced stage follicular lymphoma patients

Combined Bendamustine, Prednisone and Bortezomib (BPV) in Patients with Relapsed or Refractory Multiple Myeloma

Bacillary angiomatosis

Analysis of Hypochromic Reticulocytes and Ferritin Index as a Rationale for An Effective Therapy of Cancer- and Chemotherapy-Associated Anemia

Bazilläre Angiomatose

Bortezomib in Combination with Bendamustine and Prednisone in the Treatment of Patients with Refractory/Relapsed Multiple Myeloma

Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study

High Dose Cytarabine Salvage Regimen Combined with Bortezomib Is Feasible and Highly Effective in Relapsed Mantle Cell Lymphoma

Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology (OSHO#39)

Treatment with Bendamustine, Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Autologous Stem Cell Transplantation or Conventional Chemotherapy: Results of a Phase I Clinical Trial

Bendamustine in Combination with Thalidomide and Prednisolone (BPT) in Patients with Refractory or Relapsed Multiple Myeloma after Conventional Chemotherapy: Final Results of a Phase I Study

Results of a Prospective Randomised Open Label Phase III Study Comparing Rituximab Plus Mitoxantrone, Chlorambucile, Prednisolone Chemotherapy (R-MCP) Versus MCP Alone in Untreated Advanced Indolent Non-Hodgkin's Lymphoma (NHL) and Mantle-Cell-Lymphoma (MCL)

Cost Evaluation of Rituximab Plus MCP vs. MCP Alone in Advanced Stage Indolent Non-Hodgkin's-Lymphoma Based on a Randomized Controlled Multicenter Trial

Bacillary angiomatosis

Bazilläre Angiomatose

BODY MOVEMENT IN RELATION TO TYPE OF INFORMATION (PERSON- AND NONPERSON-ORIENTED) AND COGNITIVE STYLE (FIELD DEPENDENCE)

Suchergebnisse filtern